
Biocon, a leading biotechnology company, received a Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) for its application for Insulin Aspart, a proposed biosimilar for diabetes treatment. The CRL indicates that the initial review of the application is complete but cannot be approved in its current state. Notably, the CRL didn't highlight any scientific concerns with the product but referenced the need to address deficiencies identified during the pre-approval inspection of Biocon's Malaysia facility in August 2022. The company remains committed to working with the USFDA to resolve and approve its biosimilar Insulin Aspart application promptly.
Like
Save
Share